systemic triple therapy in metastatic hormone-sensitive prostate cancer
Published 2 years ago • 1.4K plays • Length 0:47Download video MP4
Download video MP3
Similar videos
-
4:05
evaluating triplet therapy in metastatic hormone sensitive prostate cancer
-
2:27
triplet therapy for metastatic hormone-sensitive prostate cancer
-
1:15
exciting times for hormone-sensitive prostate cancer treatment
-
16:26
patient selection in metastatic hormone-sensitive prostate cancer (mhspc)
-
1:17
treatment landscape for metastatic hormone-sensitive prostate cancer
-
3:44
the evolving standard of care for patients with metastatic hormone-sensitive prostate cancer
-
2:10
current standards for first-line metastatic hormone-sensitive prostate cancer
-
1:56
arasens: dialuramide plus adt and docetaxel for metastatic hormone-sensitive prostate cancer
-
15:37
choosing systemic therapy for men with metastatic hormone sensitive prostate cancer
-
13:09
pca commentary: metastatic hormone sensitive prostate cancer (mhspc): many treatment options
-
6:53
perspectives on metastatic hormone-sensitive prostate cancer | bayer
-
3:20
radiation therapy for the local treatment of metastatic hormone-sensitive prostate cancer
-
53:48
metastatic hormone sensitive prostate cancer - expert guidance for urologists
-
1:01:45
metastatic hormone sensitive prostate cancer: expert guidance for urologists
-
17:44
new approaches to metastatic hormone sensitive prostate cancer
-
4:52
understanding metastatic hormone-sensitive prostate cancer (mhspc) with dr. fred saad
-
1:43
dr. oh on the role of docetaxel in metastatic hormone-sensitive prostate cancer
-
1:07
dr. penson on treatment selection in metastatic hormone-sensitive prostate cancer
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer